Interfacial charge regulation of protein blocking layers in transistor biosensor for direct measurement in serum
Publication date: Available online 10 October 2019Source: Biosensors and BioelectronicsAuthor(s): Sungwook Park, Minsoo Kim, Dongkap Kim, Seok Ho Kang, Kwan Hyi Lee, Youngdo JeongAbstractIon-sensitive field-effect transistor (ISFET) as a biosensor facilitates a process of data-acquisition through label-free and real-time monitoring. Direct quantification of a biomarker in serum is challenging in ISFET biosensor since charged proteins in serum interfere transduction to electrical signals. Here, we report the fabrication of protein blocking layers (PBLs) with intended interfacial charges to minimize non-specific protein bindings on ISFET. Use of charged protein precursors enables to regulate the interfacial charge of PBLs, preserving their intrinsic electric features (neutral: hemoglobin, positively charged: lysozyme, negatively charged: BSA). The effect of this interfacial charge on the signal was demonstrated through PSMA (prostate cancer biomarker) sensing using a dual-gate ISFET biosensor. The neutral PBL showed the minimum noise compared to the negatively and positively charged PBLs, enabling the ISFET to exhibit the same detection range in untreated serum as with pre- or post-treatment (1 fg/ml to 100 ng/ml). The introduction of neutral PBLs to ISFET biosensors would allow the application of the ISFET biosensor as a point-of-care device.Graphical abstract
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Pirus Ghadjar, Thomas Wiegel
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Elise De Bleser, Piet Ost
(Intermountain Medical Center) Intermountain research team identified 87 patients who were part of the Intermountain INSPIRE Registry and had developed prostate cancer. These patients were also tested for plasma levels of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are two common omega-3 fatty acids.
Authors: Montgomery B PMID: 31730580 [PubMed - in process]
Publication date: Available online 15 November 2019Source: Meta GeneAuthor(s): Berjas Abumsimir, Mohammed Mrabti, Abdelilah Laraqui, Ahmed Ameur, Saad Ibnsouda Koraishi, Mohammed Mzibrie, Mohammed Nabil Benchekroun, Hlima Bessi, Ikram Tiabi, Ihsan Almahasneh, Moulay Mustapha EnnajiAbstractThe home box transcription factor gene (HOXB13) plays a certain role in human development and prostate tumorgenesis. Genetic alterations of HOXB13 help to explore the suspected role in prostate cancer. To determine the prevalence and clinical correlates of high-frequent mutational events in home box transcription factor (HOXB13); DNA samp...
Immunotherapy drugs have so far produced underwhelming results in prostate cancer. Now a team of researchers may have figured out why and how to make these drugs work for prostate cancer patients.
LEN GOODMAN, best known for being a head judge on TV dance competition Strictly Come Dancing, underwent a secret health battle while on the show that not even the BBC knew about at the time. The star was diagnosed with prostate cancer.
Conclusion There is no research on the intraobserver agreement analysis of 68Ga–prostate-specific membrane antigen positron emission tomography/computed tomography in the literature. Our findings are the first ones. The intraobserver agreement was almost perfect. Moreover, although 68Ga–prostate-specific membrane antigen I&T positron emission tomography/computed tomography had moderate interobserver evaluation compliance of the primary tumour, it had excellent interobserver agreement levels in local lymph node metastasis and distant metastasis evaluation.4012501255
Objective Patients with prostate cancer are monitored by prostate-specific antigen (PSA) evaluation and PET [PET/computed tomography (CT)]. The aim of our study was to evaluate correlations between PSA levels and standardized uptake values (SUV) in patients with recurrent prostate cancer. Methods We analyzed 282 prostate cancer patients undergoing PET-CT due to suspicion of recurrence. Levels of PSA and PSA change per month were analyzed, together with maximum standardized uptake value (SUVmax). Results PET/CT results were positive in 175 patients (62.1%) and negative in 107 patients (37.9%). In the positive group,...
Conclusion Primary prostatic tumor seems less likely to respond to ADT than nodal or metastatic lesions. Residual primary uptake may guide patient selection for local therapy in (oligo) metastatic prostate cancer.